Osteomyelitis - Market Insight, Epidemiology And Market Forecast - 2032

Osteomyelitis - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s ‘Osteomyelitis—Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of osteomyelitis, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The osteomyelitis market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted osteomyelitis symptoms market size from 2019 to 2032, segmented by the seven major markets. The report also covers current osteomyelitis symptoms treatment practice/algorithms, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

The United States

The EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019–2032

Osteomyelitis Disease Understanding and Treatment Algorithm

Osteomyelitis Overview

Osteomyelitis is an acute infection of the bone that can occur from direct or indirect invasion by a pathogen. Direct invasion is also referred to as exogenous or acute contagious osteomyelitis and can occur at any time if there is an open wound in the body. Indirect invasion is also referred to as endogenous or acute hematogenous osteomyelitis and usually occurs from the spread of systemic infection. Both of these types can potentially progress to subacute and chronic osteomyelitis. Acute osteomyelitis typically refers to an infection of less than 1-month duration, whereas chronic osteomyelitis refers to an infection that lasts longer than 4 weeks.

Osteomyelitis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the osteomyelitis market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight osteomyelitis market report thoroughly understands osteomyelitis symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides osteomyelitis treatment algorithms and treatment guidelines for osteomyelitis symptoms in the US, Europe, and Japan.

Optimal treatment of skeletal infections requires collaborative efforts of pediatricians, orthopedic surgeons, and interventional radiologists. Antibiotics can make up an effective treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis. Painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required.

A few major unmet needs in the market include lack of novel and effective strategies for antibiotic therapy, challenges in diagnosis, difficulty in establishing microbial etiology, antimicrobial resistance, and lack of clarity in the role of surgical debridement in treating chronic osteomyelitis.

Osteomyelitis Epidemiology

The osteomyelitis symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and its trends and assumptions.

Key Findings

The total diagnosed incident cases of osteomyelitis patients in the 7MM will increase during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted osteomyelitis symptoms epidemiology segmented as the total diagnosed incident cases of osteomyelitis, severity-specific diagnosed cases of osteomyelitis, gender-specific diagnosed cases of osteomyelitis, age-specific diagnosed cases of osteomyelitis, etiology-specific diagnosed cases of osteomyelitis, location-specific diagnosed cases of osteomyelitis, and laterality-specific diagnosed cases of osteomyelitis. The report includes the diagnosed incident cases scenario of osteomyelitis in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Osteomyelitis Epidemiology

The epidemiology segment also provides the osteomyelitis epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The diagnosed incidence cases of osteomyelitis in 7MM countries were around 162,000 in 2021.

Osteomyelitis Drug Chapters

The Osteomyelitis report’s drug chapter segment encloses the detailed analysis of osteomyelitis early-stage (Phase II and III) pipeline drugs. It also helps understand the osteomyelitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Osteomyelitis Emerging Drugs

DALVANCE (dalbavancin): Durata Therapeutics Inc.|Allergan plc

DALVANCE (dalbavancin) is a second-generation, semi-synthetic lipoglycopeptide antibiotic consisting of a lipophilic side chain added to an enhanced glycopeptide backbone. DALVANCE demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as S. aureus (including methicillin-resistant, also known as MRSA, strains) and S. pyogenes, as certain other streptococcal species.

In March 2015, the FDA granted orphan drug designation to dalbavancin for the treatment of acute osteomyelitis in children.

A Phase II study was completed evaluating the safety and efficacy of Dalbavancin versus an active comparator in adult patients with osteomyelitis known or suspected to be due to Gram-positive organisms.

Other Products detailed in the report…

Osteomyelitis Market Outlook

The report’s osteomyelitis market outlook helps understand the historic, current, and forecasted osteomyelitis market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the osteomyelitis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the osteomyelitis market in the 7MM is expected to grow steadily during the study period 2019–2032.

With the appropriate diagnostics, antibiotics can make up an effective treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis; painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required. Early diagnosis is crucial because fast antibiotic delivery may prevent permanent bone loss.

Key Findings

This section includes a glimpse of the osteomyelitis market in the 7MM.

The osteomyelitis market size in the seven major markets was more than USD 400 million in 2021.

The United States Market Outlook

This section provides the total osteomyelitis market size and market size by therapies in the United States.

The United States accounts for the largest market size of osteomyelitis compared to the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The EU5 Countries: Market Outlook

The total osteomyelitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total osteomyelitis market size and market size by therapies in Japan are also mentioned.

Osteomyelitis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to be launched in the market during 2019–2032. The analysis covers the osteomyelitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Osteomyelitis Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses osteomyelitis key players involved in developing targeted therapeutics.

Major market players include Durata Therapeutics and Basilea Pharmaceutica.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for osteomyelitis emerging therapies.

In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc in a deal worth about USD 63 billion, following receipt of regulatory approval from all government authorities required by the transaction agreement and the Irish High Court.

Reimbursement Scenario in Osteomyelitis

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the osteomyelitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or osteomyelitis market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the osteomyelitis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers a descriptive overview of osteomyelitis, explaining its causes, signs and symptoms, physiology, and currently available therapies.

Comprehensive insight into the osteomyelitis epidemiology and treatment in the 7MM.

Additionally, an all-inclusive account of the current and emerging therapies for osteomyelitis is provided, along with the assessment of new therapies that will impact the current treatment landscape.

A detailed review of the osteomyelitis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.

The report provides an edge while developing business strategies by understanding trends shaping and driving the global osteomyelitis market.

Report Highlights

In the coming years, the osteomyelitis market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs, and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence osteomyelitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Major players are involved in developing therapies for osteomyelitis. The launch of emerging therapies will significantly impact the osteomyelitis market.

Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Osteomyelitis Report Insights

Patient Population

Therapeutic Approaches

Osteomyelitis Pipeline Analysis

Osteomyelitis Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Osteomyelitis Report Key Strengths

11 years Forecast

7MM Coverage

Osteomyelitis Epidemiology Segmentation

Key Cross Competition

Highly Analyzed Market

Drugs Uptake

Osteomyelitis Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Key Questions

Market Insights:

What was the osteomyelitis Market share (%) distribution in 2019, and how would it look in 2032?

What would be the osteomyelitis total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?

What are the key findings of the market across the 7MM, and which country will have the largest osteomyelitis market size during the forecast period (2019–2032)?

At what CAGR the osteomyelitis market is expected to grow in the 7MM during the forecast period (2019–2032)?

What would be the osteomyelitis market outlook across the 7MM during the forecast period (2019–2032)?

What would be the osteomyelitis market growth till 2032, and what will be the resultant market size in 2032?

Epidemiology Insights:

What are the disease risk, burdens, and unmet needs of osteomyelitis?

What is the historical osteomyelitis patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan?

What would be the forecasted patient pool of osteomyelitis in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan?

Out of all the 7MM countries, which country would have the largest diagnosed incident population of osteomyelitis during the forecast period (2019–2032)?

At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of osteomyelitis along with the approved therapy?

What are the current treatment guidelines for treating osteomyelitis in the US, Europe, and Japan?

What are osteomyelitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?

How many companies are developing therapies for the treatment of osteomyelitis?

How many therapies are developed by each company for the treatment of osteomyelitis?

How many emerging therapies are in the mid-stage and late stages of development to treat osteomyelitis?

What are the key collaborations (Industry–Industry, Industry–Academia), mergers and acquisitions, and licensing activities related to osteomyelitis therapies?

What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for osteomyelitis and their status?

What key designations have been granted for emerging therapies for osteomyelitis?

What are the global historical and forecasted markets for osteomyelitis?

Reasons to buy

The report will help develop business strategies by understanding trends shaping and driving the osteomyelitis market.

To understand the future market competition in the osteomyelitis market and an Insightful review of the key market drivers and barriers.

Organize sales and marketing efforts by identifying the best opportunities for osteomyelitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.

Organize sales and marketing efforts by identifying the best opportunities for the osteomyelitis market.

To understand the future market competition in the osteomyelitis market.